There is enough experience with the first wave of autologous CAR-T therapies targeting CD19 and BCMA to allow strict rules ensuring their safe use to be relaxed, according to the FDA. The US regulator ...
This package can be found on PyPI.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback